Select By Rule or Topic: Download the consolidated index here
Please visit Archive to view marked-up versions and versions that have been superseded or withdrawn.
This section comprises decisions on cases handled by the Listing Committee and/or the Listing Division, to enhance transparency and market understanding of their interpretation of the Listing Rules. Each decision was based on its specific circumstances and is not a precedent for future cases.
Effective from 1 January 2011, listing decisions will be published under a new naming format as illustrated below:
|Before 1 January 2011||On or After 1 January 2011|
Listing decisions published before 1 January 2011 continue to bear the old references.
|LD Series Number||First
|Listing Rules/ Topics||Particulars|
|LD138-2022||09/2022||Main Board Rules 8.04, 8A.04 and 19C.02||To provide guidance on why the Exchange considered certain proposed applicants have not demonstrated their suitability to list with a WVR structure|
|LD137-2022||06/2022||Main Board Rule 7.27B||The Exchange was satisfied that there were exceptional circumstances for Company A to undertake the proposed issuance of shares under Rule 7.27B|
|LD136-2022||06/2022||Main Board Rule 14.06B||The Exchange ruled the proposed acquisition to be a reverse takeover|
||Main Board Rule 18A.01||Whether Product X (being one of Company A’s Core Products) which completed the Phase 1 clinical trials under the Therapeutic Goods Administration in Australia and subsequently obtained approval from both the European Medicines Agency and the National Medical Products Administration to commence the global pivotal Phase 2/3 clinical trial satisfies the relevant core product eligibility requirements under GL92-18 and Chapter 18A of the Main Board Rules|
||Main Board Rule 8.04||Whether Company X is suitable for listing in light of (a) the prolonged deterioration of financial performance of its Core Businesses (as defined below); (b) the limited track record of its new services and temporary business improvement; and (c) the failure to prove its business improvement plans|
|LD133-2022||05/2022||Main Board Rule 8.04||Whether Company X is suitable for listing in light of the material reliance on Dr. A|
|LD132-2022||05/2022||Main Board Rules 3.08 and 3.09||Whether each of Mr. A and Mr. B is suitable to act as a director of an issuer in light of bribery incidents|